The Trump administration's new executive order targets the stockpiling of active pharmaceutical ingredients (APIs) to fortify U.S. manufacturing. Despite a rise in domestic drug production, approximately 10% of APIs for finished drugs come from the U.S. Previous efforts, such as the Strategic Active Pharmaceutical Ingredient Reserve (SAPIR) initiated in 2020, aimed to address this issue. The order aims to create a list of about 26 critical medications while ensuring a six-month supply of APIs. This strategic move intends to diminish reliance on overseas resources and protect supply chains from foreign adversaries.
The Trump administration's policy goal of bringing drug manufacturing back to the U.S. is now expanding to active pharmaceutical ingredients (APIs) under a new executive order.
Nearly two in five prescription drugs are finished in the U.S., but by volume, only about 10% of APIs for these finished products are made in the U.S.
Stockpiling APIs is advantageous as APIs are generally lower-cost and have longer shelf lives than the finished drug products they make.
The order directs the Office of the Assistant Secretary for Preparedness Response (ASPR) to develop a list of about 26 critical drugs to maintain a six-month supply of APIs.
#pharmaceuticals #active-pharmaceutical-ingredients #drug-manufacturing #us-policy #supply-chain-security
Collection
[
|
...
]